Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Chief Financial Officer | September 15, 2026 | September 16, 2026 |
| TYME TECHNOLOGIES, INC.TYME · Entity 123718 | President, CFO | May 07, 2020 | May 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,071,462 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Tax withholding · Disposed 5,396 · Balance 1,071,462 F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
TYME TECHNOLOGIES, INC.
Report date May 07, 2020 · Filed May 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option - right to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2030-05-06 | Direct | 360,000 |
Reported balance
After 2020-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-07 · Grant · Acquired 360,000 · Balance 360,000 F1: This option vests over a four-year period in equal quarterly installments. |
| Employee Stock Option - right to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2027-03-27 | Direct | 1,500,000 |
Reported balance
After 2018-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-30 · Grant · Acquired 1,500,000 · Balance 1,500,000 F2: This option was originally granted on March 27, 2017 and was amended on June 30, 2018 to modify the vesting schedule as if the option vested over a three-year period in equal quarterly installments and is disclosed here for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests over a four-year period in equal quarterly installments.
F2: This option was originally granted on March 27, 2017 and was amended on June 30, 2018 to modify the vesting schedule as if the option vested over a three-year period in equal quarterly installments and is disclosed here for informational purposes only.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 21:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 5,396 | $3.41 | $18,400.36 |
DisclosureSEC source: 0001601830-26-000110 · wk-form4_1789595520.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,071,462 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 21:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 25,018 | $3.16 | $79,056.88 |
DisclosureSEC source: 0001712276-26-000009 · wk-form4_1787089461.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,858 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 5,396 | $3.15 | $16,997.40 |
DisclosureSEC source: 0001712276-26-000007 · wk-form4_1781730449.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,101,876 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:54 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 25,018 | $3.04 | $76,054.72 |
DisclosureSEC source: 0001712276-26-000005 · wk-form4_1779227682.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,107,272 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 48,028 | $3.11 | $149,367.08 |
DisclosureSEC source: 0001712276-26-000003 · wk-form4_1775681908.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,132,290 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 7,956 | $3.39 | $26,970.84 |
DisclosureSEC source: 0001712276-26-000002 · wk-form4_1773870740.xml · nonDerivative · entry 2 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,180,318 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 21:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 7,075 | $3.42 | $24,196.50 |
DisclosureSEC source: 0001712276-26-000002 · wk-form4_1773870740.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,188,274 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 13,426 | $3.08 | $41,352.08 |
DisclosureSEC source: 0001601830-26-000020 · wk-form4_1771547442.xml · nonDerivative · entry 2 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,195,349 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 00:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 11,908 | $3.49 | $41,558.92 |
DisclosureSEC source: 0001601830-26-000020 · wk-form4_1771547442.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,208,775 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 11,400 | $3.98 | $45,372.00 |
DisclosureSEC source: 0001601830-26-000013 · wk-form4_1770765498.xml · nonDerivative · entry 3 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,220,683 F3 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 24,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000013 · wk-form4_1770765498.xml · nonDerivative · entry 2 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,232,083 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 446,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000013 · wk-form4_1770765498.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,207,829 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 00:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 21,383 | $4.18 | $89,380.94 |
DisclosureSEC source: 0001712276-25-000017 · wk-form4_1767141308.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 761,550 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 23:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 7,057 | $4.33 | $30,556.81 |
DisclosureSEC source: 0001712276-25-000015 · wk-form4_1766014441.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 782,933 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 2,271 | $4.03 | $9,152.13 |
DisclosureSEC source: 0001712276-25-000013 · wk-form4_1764195265.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,990 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 00:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 11,908 | $4.14 | $49,299.12 |
DisclosureSEC source: 0001712276-25-000011 · wk-form4_1763599056.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792,261 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:45 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 7,057 | $4.83 | $34,085.31 |
DisclosureSEC source: 0001601830-25-000147 · wk-form4_1758141935.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 804,169 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 11,908 | $5.64 | $67,161.12 |
DisclosureSEC source: 0001601830-25-000133 · wk-form4_1755642130.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 811,226 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 7,057 | $4.92 | $34,720.44 |
DisclosureSEC source: 0001601830-25-000091 · wk-form4_1750278755.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 823,134 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 11,908 | $4.25 | $50,609.00 |
DisclosureSEC source: 0001601830-25-000083 · wk-form4_1747687446.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,191 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:38 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 26,571 | $5.10 | $135,379.25 |
DisclosureSEC source: 0001601830-25-000057 · wk-form4_1743712677.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 842,099 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 7,057 | $6.84 | $48,269.88 |
DisclosureSEC source: 0001601830-25-000049 · wk-form4_1742416051.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868,670 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 10,879 | $10.64 | $115,752.56 |
DisclosureSEC source: 0001601830-25-000019 · wk-form4_1740087755.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 875,727 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 70,037 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001628280-25-004088 · wk-form4_1738792233.xml · derivative · entry 4 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,037 Underlying: Class A Common Stock · 70,037 shares Expires 2035-02-03 F4 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 6,544 | $7.25 | $47,444.00 |
DisclosureSEC source: 0001628280-25-004088 · wk-form4_1738792233.xml · nonDerivative · entry 3 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 886,606 F3 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 13,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004088 · wk-form4_1738792233.xml · nonDerivative · entry 2 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 893,150 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 35,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004088 · wk-form4_1738792233.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 879,228 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 740,686 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001601830-24-000249 · wk-form4_1734729410.xml · derivative · entry 2 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 740,686 Underlying: Class A Common Stock · 740,686 shares Expires 2034-12-18 F2 · derivative.exercise_date: 1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 370,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000249 · wk-form4_1734729410.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 844,210 F1 · kind: These shares represent an award of restricted stock units which vest as to 1/16th of the shares subject to the award quarterly, beginning February 15, 2025, subject to the Mr. Taylor's continued service through each vesting date. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 23:49 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 7,057 | $6.95 | $49,046.15 |
DisclosureSEC source: 0001601830-24-000247 · wk-form4_1734565748.xml · nonDerivative · entry 2 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,867 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 23:49 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 15,668 | $6.04 | $94,634.72 |
DisclosureSEC source: 0001601830-24-000247 · wk-form4_1734565748.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,924 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 07, 2020 Filed May 18, 2020 17:41 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 360,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000899243-20-013415 · doc4.xml · derivative · entry 1 Taylor Ben R · CIK 0001712276 · President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2030-05-06 F1 · derivative.exercise_date: This option vests over a four-year period in equal quarterly installments. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 13:15 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | PurchaseCommon Stock | 10,000 | $1.01 | $10,100.00 |
DisclosureSEC source: 0000899243-19-017151 · doc4.xml · nonDerivative · entry 1 Taylor Ben R · CIK 0001712276 · President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.05, inclusive. The reporting person undertakes to provide to Tyme Technologies, Inc., any security holder of Tyme Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 03, 2019 Filed May 7, 2019 17:05 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 469,300 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000899243-19-012471 · doc4.xml · derivative · entry 1 Taylor Ben R · CIK 0001712276 · President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,300 Underlying: Common Stock · 469,300 shares Expires 2029-05-03 F1 · derivative.exercise_date: This option vests over a three-year period in equal quarterly installments. Read SEC document |
| June 30, 2018 Filed May 18, 2020 17:41 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 1,500,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0000899243-20-013415 · doc4.xml · derivative · entry 2 Taylor Ben R · CIK 0001712276 · President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2027-03-27 F2 · kind: This option was originally granted on March 27, 2017 and was amended on June 30, 2018 to modify the vesting schedule as if the option vested over a three-year period in equal quarterly installments and is disclosed here for informational purposes only. F2 · derivative.exercise_date: This option was originally granted on March 27, 2017 and was amended on June 30, 2018 to modify the vesting schedule as if the option vested over a three-year period in equal quarterly installments and is disclosed here for informational purposes only. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:33 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 400,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000899243-18-014358 · doc4.xml · derivative · entry 1 Taylor Ben R · CIK 0001712276 · President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2028-05-24 F1 · derivative.exercise_date: This option grant is subject to a four-year vesting schedule, vesting 25% on May 24, 2019, and the remaining 75% vesting on a quarterly basis over a three-year period at a rate of 1/12 per quarter. Read SEC document |
| November 22, 2017 Filed Nov 27, 2017 19:40 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 129,957 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0000899243-17-027462 · doc4.xml · derivative · entry 2 Taylor Ben R · CIK 0001712276 · President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,957 Underlying: Common Stock · 129,957 shares Expires 2019-11-22 F2 · derivative.exercise_date: This option grant is subject to a six month vesting schedule, vesting 1/6 per month beginning on December 22, 2018. Read SEC document |
| November 22, 2017 Filed Nov 27, 2017 19:40 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 50,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0000899243-17-027462 · doc4.xml · derivative · entry 1 Taylor Ben R · CIK 0001712276 · President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-11-22 F1 · derivative.exercise_date: 25,000 options are exercisable immediately, with the remaining 25,000 exercisable on November 22, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.